Geneva Biotech is a privately held biotechnology company, based in Geneva, Switzerland. Founded in 2012 as a spin-off of the European Molecular Biology Laboratory (EMBL), our vision is to develop a world class portfolio of viral and nonviral gene delivery systems and to market them across a broad spectrum of application fields.
Dr. Daniel Fitzgerald
Daniel received his PhD at Purdue (USA), carried out his post graduate studies at ETH Zürich, and has a decade long track record in publishing, patenting, and marketing novel protein production technologies. Daniel has been co-founder of two previous startups and has received several prestigious entrepreneurship prizes including the Venture prize from McKinsey & Company and the W.A. de Vigier Award.
Dr. Dominik Schelshorn
Dominik received his PhD in Neurophysiology from the University of Heidelberg (Germany). Previously Dominik led a team at Addex Therapeutics (Switzerland) in engineering novel biosensors and cellular assays for drug discovery and development with a focus on GPCR signaling.
Alicia Del Pierro
Alicia studied molecular biology at the University of Southern California (USA), and leads our sales and marketing team.
Sonya studied management and finance at Purdue University (USA), and is a CPA with nearly 20 years of industry finance experience. Sonya is heading our operations in USA as Managing Director.
Professor Imre Berger
Imre received his PhD at MIT (USA) and carried out his post graduate studies at ETH Zürich (Switzerland), was group leader at EMBL and is Professor and Wellcome Trust Senior Investigator in Bristol, UK. Imre is a world leader in developing DNA delivery tools and multi-expression systems and is a regular on the academic and industrial lecture circuits.
Our Scientific Advisory Board
Geneva Biotech is presently assembling a Scientific Advisory Board comprising experts from the world of molecular biology.